Мортен Хансен - Великие по собственному выбору

“Intel: The Microprocessor Champ Gambles on Another Leap Forward,” Business Week, April 14, 1980, 94; Mimi Real and Robert Warren, A Revolution in Progress… A History of Intel to Date (Santa Clara, CA: Intel Corporate Communications Department, 1984), 7, 46; Leslie Berlin, The Man Behind the Microchip (New York: Oxford University Press, 2005), 172.

Steven Rosenbush, Robert D. Hof, and Ben Elgin, “Too Much Cash, Too Little Innovation,” Business Week, July 18, 2005; Jeremy Quittner, “Entrepreneurs Hoard Cash,” Business Week, April 16, 2008; Ben McClure, “Cash: Can a Company Have Too Much?” Investopedia, http://boards.investopedia.com/articles/fundamental/03/062503.asp.

Tim Olper, Lee Pinkowitz, Rene Stulz, and Rohan Williamson, “The Determinants and Implications of Corporate Cash Holdings,” Journal of Financial Economics, 1999, 17. Примечание: в финансовых отчетах ликвидность страховых компаний выглядит совершенно иначе, чем в других отраслях, включенных в наше исследование. По этой причине коэффициент ликвидности Progressive в данной статистике не учитывается.

Nassim Nicholas Taleb, The Black Swan (New York: Random House, 2007); Nassim N. Taleb Home & Professional Page, http://www.fooledbyrandomness.com.

Southwest Airlines Co., Fiscal 1991 Annual Report (Dallas: Southwest Airlines Co., 1991), 3.

Terry Maxon, “Southwest Airlines’ Chances for Survival Good in Industry Crisis,” Knight Ridder/Tribune Business News, October 4, 2001; “It Must Be the Peanuts,” CFO, December 2001,48; Kim Clark, “Nothing But the Plane Truth,” U. S. News & World Report, December 31, 2001, 58; “Southwest Airlines Soars with Morningstar’s CEO of the Year Award,” PR Newswire, January 4, 2002; Southwest Airlines Co., Fiscal 2001 Annual Report (Dallas: Southwest Airlines Co., 2001), 5; Southwest Airlines Co., Fiscal 2002 Annual Report (Dallas: Southwest Airlines Co., 2002), 2.

“It Must Be the Peanuts,” CFO, December 2001, 48; Marc L. Songini, “Southwest Expands Business Tools’ Role: Will Manage Operational Data with Tools that Helped Stabilize Finances after Attacks,” Computerworld, July 15, 2002, 6; Southwest Airlines Co., Fiscal 2001 Annual Report (Dallas: Southwest Airlines Co., 2001), 4.

Good to Great, produced by Sam Tyler (Boston: Northern Light Productions, 2006), DVD.

David Breashears, High Exposure (New York: Simon & Schuster Paperbacks, 1999), 251–56, 265, 285.

Andy Grove with Bethany McClean, “Taking on Prostate Cancer,” Fortune, May 13, 1996.

Данные для этого раздела и диаграммы: Stryker Corporation, Fiscal 1989, 1990, 1992, 1994, 1996, 1997, and 1998 Annual Reports (Kalamazoo, MI: Stryker Corporation, 1989, 1990, 1992, 1994, 1996, 1997, and 1998).

Brenda Rios, “Kalamazoo, Mich., Medical Products Firm to Buy Pfizer Orthopedics Unit,” Knight Ridder/Tribune Business News, August 14, 1998; James P. Miller, “Conservative Stryker Joins the Merger Game in a Big Way,” Wall Street Journal, August 21, 1998, 1; Stryker Corporation, Fiscal 1998 Annual Report (Kalamazoo, MI: Stryker Corporation, 1998), 6.

Brenda Rios, “Kalamazoo, Mich., Medical Products Firm to Buy Pfizer Orthopedics Unit,” Knight Ridder/Tribune Business News, August 14, 1998; James P. Miller, “Conservative Stryker Joins the Merger Game in a Big Way,” Wall Street Journal, August 21,1998,1; Stryker Corporation, Fiscal 1989, 1996, 1998, and 2000 Annual Reports (Kalamazoo, MI: Stryker Corporation, 1989, 1996, 1998, and 2000).

Личная беседа с автором.

Daniel J. Simons and Christopher F. Chabris, “Gorillas in Our Midst: Sustained Inattentional Blindness for Dynamic Events,” Perception, 1999, 1059–70.

Фамилия мистера Бакаута встречается в трех разных написаниях. Мы выбрали вариант, используемый в официальной истории Intel за 15 лет. Mimi Real and Robert Warren, A Revolution in Progress… A History of Intel to Date (Santa Clara, CA: Intel Corporate Communications Department, 1984), 15.

William H. Davidow, Marketing High Technology (New York: The Free Press, 1986), 1–11; Mimi Real and Robert Warren, A Revolution in Progress… A History of Intel to Date (Santa Clara, CA: Intel Corporate Communications Department, 1984), 15.

Mimi Real and Robert Warren, A Revolution in Progress… A History of Intel to Date (Santa Clara, CA: Intel Corporate Communications Department, 1984), 15; William H. Davidow, Marketing High Technology (New York: The Free Press, 1986), 4–6.

William H. Davidow, Marketing High Technology (New York: The Free Press, 1986), 7–8, 10; Katie Woodruff, Defining Intel: 25 Years/25 Events (Santa Clara, CA: Intel Corporation, 1993), 16; Tim Jackson, Inside Intel: Andy Grove and the Rise of the World’s Most Powerful Chip Company (New York: Plume, 1997), 194.

Gordon M. Binder, Amgen (n.p. The Newcomen Society of the United States, 1998), 12; David Ewing Duncan, The Amgen Story: 25 Years of Visionary Science and Powerful Medicine (San Diego: Tehabi Books, 2005), 84–85.

Ellen Benoit, “Breakfast at the Ritz,” Financial World, March 10, 1987, 18; Marilyn Chase, “FDA Panel Rejection of Anti-Clot Drug Sets Genentech Back Months, Perils Stock,” Wall Street Journal, June 1, 1987, 26; Jesus Sanchez, “Rejection of Genentech’s Heart Drug Surprises Biotechnology Investors,” Los Angeles Times, June 2, 1987, 1; Stuart Gannes and Gene Bylinsky, “The Big Boys are Joining the Biotech Party: Corporate Giants are about to Crowd the Start-Ups,” Fortune, July 6, 1987, 58; Andrew Pollack, “Taking the Crucial Next Step at Genentech,” New York Times, January 28, 1990.

Jesus Sanchez, “Rejection of Genentech’s Heart Drug Surprises Biotechnology Investors,” Los Angeles Times, June 2, 1987, 1; Brenton R. Schlender, “Genentech’s Missteps and FDA Policy Shift Led to TPA Setback,” Wall Street Journal, June 16, 1987, 1.

Marilyn Chase, “FDA Panel Rejection of Anti-Clot Drug Sets Genentech Back Months, Perils Stock,” Wall Street Journal, June 1, 1987, 26; Jesus Sanchez, “Rejection of Genentech’s Heart Drug Surprises Biotechnology Investors,” Los Angeles Times, June 2, 1987, 1; “Paradise Postponed,” Economist, June 6, 1987; “Genentech, Biotechnology Stocks Tumble After Ruling on TPA Drug for Blood Clots,” Wall Street Journal, June 2, 1987, 3.

Reginald Rhein Jr., “FDA Pulls Out the Stops to Approve Genentech’s TPA,” Chemical Week, November 25, 1987, 9.

Joan O’C. Hamilton and Reginald Rhein Jr., “A Nasty Shock for Genentech,” Business Week, June 15, 1987, 37; Reginald Rhein Jr., “FDA Pulls Out the Stops to Approve Genentech’s TPA,” Chemical Week, November 25, 1987, 10.